The donation will directly support the VIC’s work to develop a vaccine and novel point of care testing technologies for COVID-19, which is critical to start opening up the economy and increase safety of healthcare workers and their patients.
Analog Devices and the VIC are supporting a trial to develop and deploy two new tests to identify and confirm which individuals have a detectable immune response to COVID-19 and are virus negative. ADI and the VIC will also seek ways to leverage ADI’s sensing technologies to develop rapid care tests and real-time remote vital sign monitoring for COVID-19 patients in quarantine.
“Analog Devices is proud to work with Massachusetts General Hospital’s Vaccine & Immunotherapy Center as it works tirelessly to discover the testing solutions required to identify COVID-19 in individuals and slow the spread of the virus,” said Vincent Roche, President and CEO of ADI. “There is no better teammate in this fight than this prestigious medical research institution and we look forward to working together to apply sensing technology to testing and monitoring for COVID-19 patients.”
“We know that many individuals infected with COVID-19 have still not been able to access testing to confirm the diagnosis,” said Dr. Poznansky, MD, PhD, and Associate Professor of Medicine at Harvard Medical School and Attending Physician in General and Transplant Infectious Diseases at MGH. “Additionally, there are many others who might have been infected but are unaware because they were asymptomatic. Confirming immunity and viral negativity will be critical to both beginning to help open up key sectors of society and identifying those that can relatively safely interact amongst others and those who should remain in quarantine.”
The MGH VIC was founded in 2008 to accelerate the translation of laboratory discoveries into new, safe, and broadly applicable cost-effective vaccines and therapies to prevent and cure various forms of cancer, infectious and immune mediated diseases. VIC has nine medical products currently in development and three have entered human testing.